Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Non-Current Assets (2016 - 2025)

Avanos Medical (AVNS) has disclosed Non-Current Assets for 13 consecutive years, with $718.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 5.59% to $718.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, down 33.52% year-over-year, with the annual reading at $718.3 million for FY2025, 5.59% down from the prior year.
  • Non-Current Assets hit $718.3 million in Q4 2025 for Avanos Medical, roughly flat from $716.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.3 billion in Q1 2022 to a low of $683.0 million in Q2 2025.
  • Historically, Non-Current Assets has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2021.
  • Biggest five-year swings in Non-Current Assets: increased 10.53% in 2022 and later crashed 42.3% in 2025.
  • Year by year, Non-Current Assets stood at $1.2 billion in 2021, then decreased by 1.12% to $1.2 billion in 2022, then increased by 3.66% to $1.2 billion in 2023, then crashed by 36.88% to $760.8 million in 2024, then fell by 5.59% to $718.3 million in 2025.
  • Business Quant data shows Non-Current Assets for AVNS at $718.3 million in Q4 2025, $716.3 million in Q3 2025, and $683.0 million in Q2 2025.